(estimated mean changes of -2 to +5%). Co-administration of lersivirine at steady-state 44 with maraviroc resulted in no clinically relevant effects on maraviroc AUC tau , C max , or C 12 45
maraviroc without the need for dose modification.
INTRODUCTION Study design. 120
The studies were both open-label, randomized crossover trials with screening visits 121 occurring up to 28 days before commencement of treatment. An overview of the studies, 122
including the dose and schedule of lersivirine and the co-administered drug, the number 123 of subjects, study design, length of treatment, and washout periods, is shown in Table 1 . 124
In both studies, on the PK sampling day (final day of treatment) subjects were dosed in a 125 fasted state (Study 1, morning dose only). Food was allowed from 4 hours postdose and 126 water was allowed starting from 1 hour postdose. 127
Pharmacokinetic sampling and analysis. 128
Blood samples for lersivirine, raltegravir, and/or maraviroc analyses were collected on the 129 final day of treatment in each period at 0 hours (pre-dose) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 130 12 hours post-dose. Lersivirine and maraviroc PK samples were collected into lithium 131 heparin and raltegravir PK samples into Di-potassium EDTA. Blood samples were 132
centrifuged at approximately 1700 x g for 10 minutes at 4° C and the plasma stored incontinue treatment on Days 11 to 14, and the dose of maraviroc would be increased to 139 compensate for the effect of lersivirine. If an estimated difference of <25% was observed 140 the study was to stop at Day 10 in both periods. 141
Plasma was analyzed using validated liquid chromatography/mass spectrometry 142 methodology with lower limits of quantification of 1.0 ng/mL for lersivirine and 143 raltegravir (Covance Bioanalytical Services, LLC [Indianapolis, IN, USA]), and 144 0.5 ng/mL for maraviroc (Tandem Labs [West Trenton, NJ, USA]) (2). In Study 1 the 145 precision for the lersivirine assay was ≤6.2% coefficient of variance (%CV) with an 146 accuracy of -3.7-2.0% relative error (%RE), and the precision and accuracy for the 147 raltegravir assay were ≤4.8 %CV and -0.9-1.0 %RE, respectively. In Study 2 the 148 precision and accuracy for the maraviroc assay were 6.0 %CV and -6.0-3.3 %RE, 149 respectively. Pharmacokinetic parameters for lersivirine and raltegravir (Study 1) or 150 maraviroc (Study 2) were calculated for each subject, for each treatment, from plasma 151 concentration-time profiles using standard non-compartmental methods with eNCA, a 152 In Study 1, for estimating the effect on pharmacokinetics of lersivirine, a sample size of 165 18 subjects was required to provide 90% confidence intervals (CIs) for the difference 166 between treatments of ±0.101 and ±0.140 on the natural log scale for AUC tau and C max , 167 respectively with 90% coverage probability. For estimating the effect on the 168 pharmacokinetics of raltegravir, a sample size of 18 subjects (three subjects per sequence) 169 was required to provide 90% CIs for the difference between treatments of ±0.189 and 170 ±0.270 on the natural log scale for AUC 12 and C max , respectively, with 90% coverage 171 probability. In Study 2 (maraviroc), a sample size of 12 subjects was required to provide 172 90% CIs for the difference between treatments of ±0.215 and ±0.392 on the natural log 173 scale for maraviroc AUC tau and C max , respectively with 80% coverage probability.raltegravir), C 24 (for lersivirine), and C 12 (for maraviroc and raltegravir) values were 177 analyzed separately for each compound in each study using a mixed-effect model with 178 sequence, period, and treatment as fixed effects and subject within sequence as a random 179 effect using SAS software package 8.2 (SAS Institute Inc., Cary, NC, USA). Estimates of 180 the adjusted mean differences (test-reference) and corresponding 90% CIs were obtained 181 from the model. The adjusted mean differences and 90% CIs for the differences were 182 exponentiated to provide estimates of the ratio of adjusted geometric means 183 (test/reference) and 90% CIs for the ratios. In Study 1, for the lersivirine comparison, 184 lersivirine plus raltegravir was the test treatment and lersivirine alone was the reference 185 treatment. For the raltegravir comparison, raltegravir plus lersivirine was the test 186 treatment and raltegravir alone was the reference treatment. In Study 2, maraviroc plus 187 lersivirine was the test treatment and maraviroc alone was the reference treatment. 188
RESULTS

189
Subjects. 190
In total, 18 subjects participated in Study 1 and 14 subjects participated in Study 2. None 191 of the subjects had presenting conditions or medical histories that were considered 192 sufficient to affect the conduct of the study or to represent a potential risk to the subject 193 during study participation. Subject demographics and baseline characteristics are shown 194 in Table 2 . Two subjects discontinued from Study 1 due to AEs (vomiting and dizziness)while receiving lersivirine 1000 mg QD and raltegravir 400 mg BID during Period 1 of 196 the study. 197
Pharmacokinetics. 198
Study 1: lersivirine and raltegravir. 199
When administered in the presence of raltegravir at steady state, the median plasma 200 exposure of lersivirine was unchanged compared with that observed for lersivirine alone 201 (Fig. 1) . The ratios of adjusted geometric means of lersivirine were close to 1.0 for 202 AUC tau , C max , and C 24 (Table 3 ) and median T max was reduced in the presence of 203 raltegravir from 3 hours to 2 hours. 204
In contrast, co-administration with lersivirine reduced the median plasma exposure of 205 raltegravir, compared with that observed for raltegravir alone (Fig. 2) . The ratios of 206 adjusted geometric means for AUC tau and C max suggested reductions of 15% and 29%, 207 respectively; however, C 12 was increased by 25% (Table 4) . There was no change in 208 median T max between the treatment groups. 209
Study 2: maraviroc and lersivirine. 210
In Period 1 the maraviroc C av(2-4) , Day7/Day1 ratio was estimated to be 98% (90% CI: 211 59%, 165%), indicating that no dose adjustment was required for Days 11-14. Therefore 212 the last dose in both periods was administered on Day 10. Co-administration of 213 maraviroc and lersivirine resulted in a small increase in the median maraviroc exposure 214 when compared with maraviroc and placebo (Fig. 3) . The ratios of adjusted geometricmeans of maraviroc for AUC tau , C max , and C 12 showed increases of approximately 6.2%, 216 3.4%, and 8.6%, respectively, while receiving maraviroc and lersivirine when compared 217 to maraviroc and placebo (Table 5 ). Co-administration had no effect on median T max , 3 218 hours. 219
Safety. 220
Co-administration of lersivirine with raltegravir or maraviroc was generally well tolerated 221 in these small cohorts of healthy subjects. AEs in the two studies were predominantly 222 gastrointestinal related (Table 6) 
